Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma

Merck has received approval from the European Commission (EC) for Keytruda (pembrolizumab) to treat adult patients affected with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentu …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news